New combination treatments in the management of asthma: focus on fluticasone/vilanterol

References

• BarnettSBNurmagambetovTACosts of asthma in the United States: 2002–2007J Allergy Clin Immunol2011127114515221211649
   PubMed Web of Science ®Google Scholar
• ShamsMRFinemanSMAsthma adherence: how can we help our patients do it better?Ann Allergy Asthma Immunol2014112191224331386
   PubMed Web of Science ®Google Scholar
• RichardsonKKennyRAPeklarJAgreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50 years varied by therapeutic group and reporting of indicated health conditionsJ Clin Epidemiol2013661308131623968693
   PubMed Web of Science ®Google Scholar
• IngersollKSCohenJThe impact of medication regimen factors on adherence to chronic treatment: a review of literatureJ Behav Med200831321322418202907
   PubMed Web of Science ®Google Scholar
• ColemanCILimoneBSobierajDMDosing frequency and medication adherence in chronic diseaseJ Manag Care Pharm201218752753922971206
   PubMed Web of Science ®Google Scholar
• AlbertsonTESchivoMZekiAAThe pharmacological approach to the elderly COPD patientDrugs Aging201330747950223580319
   PubMed Web of Science ®Google Scholar
• LouieSZekiAASchivoMThe asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerationsExpert Rev Clin Pharmacol20136219721923473596
   PubMed Web of Science ®Google Scholar
• ElwardKSPollartSMMedical therapy for asthma: updates from the NAEPP GuidelinesAm Fam Physician201082101242125121121536
   PubMed Web of Science ®Google Scholar
• UrbanoFLReview of the NAEPP 2007 Expert Panel Report (EPR-3) on Asthma Diagnosis and Treatment GuidelinesJ Manag Care Pharm2008141414918240881
   PubMed Web of Science ®Google Scholar
• AlbertsonTESchivoMGidwaniNPharmacotherapy of critical asthma syndrome: current and emerging therapiesClin Rev Allergy Immunol Epub1122013
   Web of Science ®Google Scholar
• CrimCPierreLNDaley-YatesPTA review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoateClin Ther20012391339135411589253
   PubMed Web of Science ®Google Scholar
• RaissyHHKellyHWHarkinsMSzeflerSJInhaled corticosteroids in lung diseasesAm J Respir Crit Care Med2013187879880323370915
   PubMed Web of Science ®Google Scholar
• SzeflerSJMartinRJKingTSAsthma Clinical Research Network of the National Heart Lung, and Blood InstituteSignificant variability in response to inhaled corticosteroids for persistent asthmaJ Allergy Clin Immunol2002109341041811897984
   PubMed Web of Science ®Google Scholar
• MartinRJSzeflerSJKingTSNational Heart, Lung, and Blood Institute’s Asthma Clinical Research CenterThe Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trialJ Allergy Clin Immunol20071191738017208587
   PubMed Web of Science ®Google Scholar
• ShepherdJRogersGAndersonRSystematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and overHealth Technol Assess20081219iiiiv1360
   Web of Science ®Google Scholar
• WoodcockABleeckerERBusseWWFluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthmaRespir Res20111216022188590
   PubMed Web of Science ®Google Scholar
• BusseWWBleeckerERBatemanEDFluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trialThorax2012671354121828231
   PubMed Web of Science ®Google Scholar
• MedleyHOrozcoSAllenAEfficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthmaClin Ther20123481683169522796247
   PubMed Web of Science ®Google Scholar
• Panina-BordignonPMazzeoDLuciaPDBeta2-agonists prevent Th1 development by selective inhibition of interleukin 12J Clin Invest19971006151315199294119
   PubMed Web of Science ®Google Scholar
• AggarwalPBhoiSComparing the efficacy and safety of two regimens of sequential systemic corticosteroids in the treatment of acute exacerbation of bronchial asthmaJ Emerg Trauma Shock20103323123720930966
   PubMedGoogle Scholar
• KramerJMBalancing the benefits and risks of inhaled long-acting beta-agonists – the influence of valuesN Engl J Med2009360161592159519369665
   PubMed Web of Science ®Google Scholar
• BacharierLBStep-down therapy in asthma: a focus on treatment options for patients receiving inhaled corticosteroids and long-acting beta-agonist combination therapyAllergy Asthma Proc2012331131822183083
   PubMed Web of Science ®Google Scholar
• SykesDACharltonSJSlow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonistsBr J Pharmacol201216582672268321883146
   PubMed Web of Science ®Google Scholar
• PatelSSummerhillSStanleyMPerros-HuguetCTrevethickMAThe reassertion profiles of long acting beta2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptorPulm Pharmacol Ther201124224725521134482
   PubMed Web of Science ®Google Scholar
• LötvallJBatemanEDBleeckerER24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroidsEur Respir J201240357057922362859
   PubMed Web of Science ®Google Scholar
• ProcopiouPABarrettVJBevanNJSynthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approachJ Med Chem201053114522453020462258
   PubMed Web of Science ®Google Scholar
• KempsfordRNorrisVSiedererSVilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPDPulm Pharmacol Ther201326225626423232038
   PubMed Web of Science ®Google Scholar
• DucharmeFMNi ChroininMGreenstoneILassersonTJAddition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthmaCochrane Database Syst Rev20104CD00553320393943
   PubMed Web of Science ®Google Scholar
• LazarusSCBousheyHAFahyJVAsthma Clinical Research Network for the National Heart, Lung, and Blood InstituteLong-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trialJAMA2001285202583259311368732
   PubMed Web of Science ®Google Scholar
• BenderBMilgromHApterAAdherence intervention research: what have we learned and what do we do next?J Allergy Clin Immunol2003112348949413679805
   PubMed Web of Science ®Google Scholar
• BenderBMilgromHRandCNonadherence in asthmatic patients: is there a solution to the problem?Ann Allergy Asthma Immunol1997793177185 quiz 185–1869305223
   PubMed Web of Science ®Google Scholar
• OnyirimbaFApterAReisineSDirect clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherenceAnn Allergy Asthma Immunol200390441141512722963
   PubMed Web of Science ®Google Scholar
• ChmelikFDoughtyAObjective measurements of compliance in asthma treatmentAnn Allergy19947365275327998669
   PubMedGoogle Scholar
• LindsayJTHeaneyLGNonadherence in difficult asthma – facts, myths, and a time to actPatient Prefer Adherence2013732933623723690
   PubMed Web of Science ®Google Scholar
• LötvallJBakkePSBjermerLEfficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trialBMJ Open201221e000370
   PubMed Web of Science ®Google Scholar
• MartinezFJBosciaJFeldmanGFluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trialRespir Med2013107455055923332861
   PubMed Web of Science ®Google Scholar
• KerwinEMScott-WilsonCSanfordLA randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPDRespir Med2013107456056923352226
   PubMed Web of Science ®Google Scholar
• BosciaJAPudiKKZvarichMTSanfordLSiedererSKCrimCEffect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover studyClin Ther20123481655166622789766
   PubMed Web of Science ®Google Scholar
• DransfieldMTBorbeauJJonesPWFluticasone furoate and vilanterol for COPDLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• WoodcockABleeckerERLötvallJEfficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trialChest201314441222122923846316
   PubMed Web of Science ®Google Scholar
• OliverABjermerLQuinnDModulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combinationAllergy20136891136114223924233
   PubMed Web of Science ®Google Scholar
• O’ByrnePMBleeckerERBatemanEDOnce-daily fluticasone furoate alone or combined with vilanterol in persistent asthmaEur Respir J201443377378224136330
   PubMed Web of Science ®Google Scholar
• BatemanEDO’ByrnePMBusseWWOnce-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF aloneThorax Epub11192013
   Web of Science ®Google Scholar
• KempsfordRDOliverABalJTombsLQuinnDThe efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosingRespir Med2013107121873188024200619
   PubMed Web of Science ®Google Scholar
• TammMRichardsDHBegheBFabbriLInhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practiceRespir Med2012106Suppl 1S9S1923273165
   PubMed Web of Science ®Google Scholar
• HananiaNAChapmanKRKestenSAdverse effects of inhaled corticosteroidsAm J Med19959821962087847437
   PubMed Web of Science ®Google Scholar
• AllenASchenkenbergerITrivediRInhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled studyClin Respir J20137439740623578031
   PubMed Web of Science ®Google Scholar
• AllenAThe relationship between fluticasone furoate systemic exposure and cortisol suppressionClin Pharmacokinet2013521088589623719680
   PubMed Web of Science ®Google Scholar
• BusseWWO’ByrnePMBleeckerERSafety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trialThorax201368651352023440247
   PubMed Web of Science ®Google Scholar
• MattishentKThavarajahMBlancoPMeta-Review: Adverse Effects of Inhaled Corticosteroids Relevant to Older PatientsDrugs2014 In press 2014
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews20143CD01011524615270
   PubMed Web of Science ®Google Scholar
• NelsonHSWeissSTBleeckerERYanceySWDorinskyPMSMART Study GroupThe Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterolChest20061291152616424409
   PubMed Web of Science ®Google Scholar